In a welcome move, Viking Therapeutics saw its Relative Strength Rating improve from 61 to 73 on Wednesday.
When To Sell Stocks To Lock In Profits And Minimize Losses
IBD's proprietary RS Rating identifies technical performance by showing how a stock's price action over the last 52 weeks measures up against that of the other stocks in our database.
Decades of market research reveals that the best stocks tend to have an 80 or better RS Rating as they begin their biggest price moves. See if Viking Therapeutics can continue to show renewed price strength and hit that benchmark.
Viking Therapeutics is now considered extended and out of buy range after clearing a 3.50 buy point in a first-stage double bottom. See if the stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week line.
Viking Therapeutics posted 0% EPS growth in the latest quarterly report. Revenue gains came in at 0%.
Viking Therapeutics holds the No. 295 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals, Halozyme Therapeutics and Rigel Pharmaceuticals are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
